Back to today’s briefing

Story perspectives

Gilead Acquires Ouro Medicines for $2 Billion Deal

3/24/2026

27 4 Full Breakdown

Summary

Gilead Acquires Ouro

Gilead Sciences is finalizing an up-to-$2 billion deal to acquire Ouro Medicines, with $1.5 billion upfront and $500 million tied to milestones.
Ouro focuses on autoimmune treatments, including the antibody drug gamgertamig, in early-stage trials for hemolytic anemia.
This follows Gilead's $7.8 billion purchase of Arcellx to bolster its cancer portfolio.
The move signals growth aims as Veklury sales decline.

Summary

Gilead Acquires Arcellx

Gilead Sciences will acquire Arcellx for about $7.8 billion, paying $115 per share in cash plus a $5 per share contingent value right tied to future sales of antocabtagene autoleucel.
Kite Pharma, a Gilead subsidiary, is already collaborating with Arcellx on this BCMA-directed CAR-T therapy for multiple myeloma.
The U.S. FDA has accepted a biologics license application for antocabtagene autoleucel, with a decision expected December 23, 2026.

1 of 2

Gilead Acquires Ouro

Gilead Sciences is finalizing an up-to-$2 billion deal to acquire Ouro Medicines, with $1.5 billion upfront and $500 million tied to milestones.
Ouro focuses on autoimmune treatments, including the antibody drug gamgertamig, in early-stage trials for hemolytic anemia.
This follows Gilead's $7.8 billion purchase of Arcellx to bolster its cancer portfolio.
The move signals growth aims as Veklury sales decline.

1 / 2